UK’s NICE Says Alzheimer’s Disease Drug Kisunla Is Not Cost-Effective
The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness ...
pharmaphorum18h
Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal casts long shadow
Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...
Biogen partner Eisai completes FDA submissions for injectable Alzheimer’s therapy
Eisai (ESAIY) completes BLA submissions for an injectable version of its Biogen (BIIB)-partered Alzheimer's drug Leqembi in ...
The American Journal of Managed Care3d
Contributor: The Era of Disease-Modifying Alzheimer Disease Treatments
New treatments for Alzheimer disease don’t reverse cognitive symptoms, but they do significantly slow progression. Evidence suggests that earlier treatment is most effective.
Donanemab – what we know about the latest Alzheimer’s drug
Donanemab can slow the progression of Alzheimer’s disease. But what is the drug and how does it work? Here your questions on ...
The Brighterside of News on MSN14d
FDA-approved Alzheimer’s drug could save lives by inducing a state of “suspended animation”
Researchers at Harvard University’s Wyss Institute for Biologically Inspired Engineering have discovered a potential ...
BioSpace7d
Lilly Lowers Brain Swelling With Modified Dosing of Alzheimer’s Drug Kisunla
Approved by the FDA in July to treat adults with early symptomatic Alzheimer’s disease, Eli Lilly’s Kisunla reduced the brain ...
Gradual dosing of Lilly Alzheimer's drug cuts brain-swelling risk, study finds
Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients ...
Top aging expert says these 4 FDA-approved drugs hold promise for extending life
Geroscience has a long way to go, but there are four FDA-approved drugs that have shown promise to “target the process of ...
Seeking Alpha15d
BioArctic AB: The David Against Goliath Of Solving Alzheimer's Disease
BioArctic's Leqembi, the first FDA-approved Alzheimer's drug, faces EMA rejection but could see a stock surge with a positive reexamination decision in November. Despite the EMA setback ...
pharmaphorum4d
Lilly gets FDA OK for Alzheimer’s drug, cites cost advantage
which is currently under FDA review. Approval for a monthly IV dose of Leqembi is also being sought. The Alzheimer’s Drug Discovery Foundation (ADDF) also welcomed the approval, saying it would ...